Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects
Authors:
- George G ZhanelGZGeorge G Zhanel
- Lavern VercaigneLVLavern Vercaigne
- the Canadian Carbapenem Discussion Group,TGthe Canadian Carbapenem Discussion Group,
Open Access
- 11 November 1997
- journal article
- research article
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 9 (4) , 215-228
Abstract
OBJECTIVE: To compare and contrast imipenem and meropenem in terms of in vitro activity, pharmacokinetics, clinical efficacy and adverse effects.DATA SELECTION: MEDLINE search from 1975 to 1997 and follow‐up of references.DATA EXTRACTION: Clinical trials comparing imipenem with meropenem, or either imipenem or meropenem with standard therapy in the treatment of serious infections were selected.DATA SYNTHESIS: Imipenem, the first carbapenem, was first marketed in 1987; meropenem was introduced to the market in 1996. In general, imipenem is more active against Gram‐positive cocci while meropenem is more active against Gram‐negative bacilli. The agents display similar pharmacokinetics. Clinical studies in patients with serious infections (intra‐abdominal infection, respiratory infection, septicemia, febrile neutropenia) report similar bacteriological and clinical cure rates with imipenem and meropenem. Meropenem is approved for the treatment of bacterial meningitis, whereas imipenem is not. Adverse effects are similar.CONCLUSIONS: Current literature supports the use of imipenem at a dose of 500 mg every 6 h and meropenem at 1 g every 8 h for the treatment of severe infections. For the treatment of serious infections, imipenem (500 mg every 6 h or 2 g/day [$98/day]) is more economical than meropenem (1 g every 8 h or 3 g/day [$142/day]) based on acquisition cost.Keywords
This publication has 103 references indexed in Scilit:
- MeropenemDrugs, 1995
- Comparison of Ciprofloxacin with Imipenem in the Treatment of Severe Pneumonia in Hospitalised Geriatric PatientsDrugs, 1995
- Pharmacokinetic Contributions to Postantibiotic EffectsClinical Pharmacokinetics, 1994
- In vitro activity of three carbapenem antibiotics comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwideDiagnostic Microbiology and Infectious Disease, 1993
- CarbapenemasesJournal of Antimicrobial Chemotherapy, 1992
- In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolatesDiagnostic Microbiology and Infectious Disease, 1990
- Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolatesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338European Journal of Clinical Microbiology & Infectious Diseases, 1989
- Imipenem/CilastatinDrugs, 1987
- In vitro activity of imipenem — A reviewEuropean Journal of Clinical Microbiology & Infectious Diseases, 1984